Tuesday, April 09, 2024 5:14:19 PM
No, not at all. Your lack of understanding the exceptions to adequate and well controlled studies and regulator influence on trial design that was actually beneficial to the patients is your problem not that of the longs, regulators or the patients. Longs are the ones who understand this and that dilution until approval and proof of expected revenue stream that points to profitability by a certain time frame is what keeps the price down with plenty of help from manipulators along the way.
Traders want to see swings in the mean time to make more money while longs keep absorbing the dilution without the help of excited new investors hoping for a quick return on investment. This makes movement of share price relatively easy with small moves one way or the other. When news hits those who were short will go long and work the swings on the way up and back down after being over bought which won’t really happen until institutions get their fill. We are just in the doldrums of retail accumulation and company sales of shares to keep the lights on until news. Unlike what you profess I am looking for the big gap up day that will never be filled because the science and methodology will win the day. It will also likely be utilized as an example in future guidance about how to navigate and overcome some tricky patient welfare considerations during trial setup that might lead to a change in adjudication methods of treatment effect before unblinding. Best wishes.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM